Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae

Vaccine

Volumn 24, Issue 37-39, 2006, Pages 6272-6281

  Wadle, Andreas ^a   Held, Gerhard ^b   Neumann, Frank ^b   Kleber, Sascha ^a   Wuellner, Beate ^b   Asemissen, Anne Marie ^c   Kubuschok, Boris ^b   Scheibenbogen, Carmen ^c   Breinig, Tanja ^b   Meyerhans, Andreas ^b   Renner, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cross presentation; CTL; MHC peptide complexes; Peptide processing presentation; Phage library

Indexed keywords

ANTIBODY; CELL EXTRACT; EPITOPE; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; INFLUENZA MATRIX PROTEIN; PEPTIDE DERIVATIVE; PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; BACTERIOPHAGE; CELL WALL; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; FUNGAL STRAIN; GENETIC ENGINEERING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SACCHAROMYCES CEREVISIAE; T LYMPHOCYTE; YEAST CELL;

ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGENS, CD14; ANTIGENS, CD86; CROSS-PRIMING; DENDRITIC CELLS; ENDOCYTOSIS; HLA-A ANTIGENS; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN FRAGMENTS; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 33747617103     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.096     Document Type: Article

References (44)

1. + T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 3 (2003) 15
2. Tsuruma T., Hata F., Furuhata T., et al. Peptide-based vaccination for colorectal cancer. Expert Opin Biol Ther 5 6 (2005) 799-807
3. + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97 22 (2000) 12198-12203
4. Dutoit V., Taub R.N., Papadopoulos K.P., et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110 12 (2002) 1813-1822
5. Gnjatic S., Jager E., Chen W., et al. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 99 18 (2002) 11813-11818
6. Singh M., and O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 17 11 (1999) 1075-1081
7. Jager E., Ringhoffer M., Dienes H.P., et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67 1 (1996) 54-62
8. Rodolfo M., and Colombo M.P. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 19 1 (1999) 114-120
9. Suhrbier A. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev Vaccines 1 2 (2002) 207-213
10. Palmowski M.J., Choi E.M., Hermans I.F., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 168 9 (2002) 4391-4398
11. Davis I.D., Chen W., Jackson H., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101 29 (2004) 10697-10702
12. Matsuo M., Nagata Y., Sato E., et al. IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci USA 101 40 (2004) 14467-14472
13. Mellman I., and Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106 3 (2001) 255-258
14. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20 (2002) 621-667
15. Brossart P., and Bevan M.J. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90 4 (1997) 1594-1599
16. Norbury C.C., Chambers B.J., Prescott A.R., Ljunggren H.G., and Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 27 1 (1997) 280-288
17. Nagata Y., Ono S., Matsuo M., et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 99 16 (2002) 10629-10634
18. Schnurr M., Chen Q., Shin A., et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105 6 (2005) 2465-2472
19. Bozza S., Gaziano R., Lipford G.B., et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 4 13 (2002) 1281-1290
20. Timmerman J.M., and Levy R. The history of the development of vaccines for the treatment of lymphoma. Clin Lymphoma 1 2 (2000) 129-139 discussion 140
21. Marchand M., Punt C.J., Aamdal S., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39 1 (2003) 70-77
22. Stubbs A.C., Martin K.S., Coeshott C., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7 5 (2001) 625-629
23. Mischo A., Wadle A., Watzig K., et al. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun 3 (2003) 5
24. Schmittel A., Keilholz U., Bauer S., et al. Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. J Immunol Methods 247 1-2 (2001) 17-24
25. Held G., Matsuo M., Epel M., et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 34 10 (2004) 2919-2929
26. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 5284 (1996) 94-96
27. Robert B., Guillaume P., Luescher I., Romero P., and Mach J.P. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 30 11 (2000) 3165-3170
28. Hoogenboom H.R., Griffiths A.D., Johnson K.S., Chiswell D.J., Hudson P., and Winter G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19 15 (1991) 4133-4137
29. Minsky A., Summers R.G., and Knowles J.R. Secretion of beta-lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc Natl Acad Sci USA 83 12 (1986) 4180-4184
30. Henderikx P., Kandilogiannaki M., Petrarca C., et al. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 58 19 (1998) 4324-4332
31. Wagner C., Neumann F., Kubuschok B., et al. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer Immun 3 (2003) 18
32. Scheibenbogen C., Lee K.H., Mayer S., et al. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3 2 (1997) 221-226
33. Hoet R.M., Cohen E.H., Kent R.B., et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 23 3 (2005) 344-348
34. Wadle A., Mischo A., Imig J., et al. Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer 117 1 (2005) 104-113
35. Schreuder M.P., Mooren A.T., Toschka H.Y., Verrips C.T., and Klis F.M. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol 14 4 (1996) 115-120
36. Tsunetsugu-Yokota Y., Morikawa Y., Isogai M., et al. Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J Virol 77 19 (2003) 10250-10259
37. Underhill D.M., and Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14 1 (2002) 103-110
38. Heintel T., Breinig F., Schmitt M.J., and Meyerhans A. Extensive MHC class I-restricted CD8 T lymphocyte responses against various yeast genera in humans. FEMS Immunol Med Microbiol 39 3 (2003) 279-286
39. Inaba K., Turley S., Yamaide F., et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 188 11 (1998) 2163-2173
40. Rios-Hernandez M., Dos-Santos N.J., Silvia C., Bello-Garciga J.L., and Pedroso M. Immunopharmacological studies of beta-1,3-glucan. Arch Med Res 25 2 (1994) 179-180
41. Roeder A., Kirschning C.J., Rupec R.A., Schaller M., Weindl G., and Korting H.C. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 42 6 (2004) 485-498
42. Aliberti J., Jankovic D., and Sher A. Turning it on and off: regulation of dendritic cell function in Toxoplasma gondii infection. Immunol Rev 201 (2004) 26-34
43. Cohn A., O'Neil M.A.M.B., Bellgrau D., Duke R.C., Franzusoff A.J., Munson S., Ferraro J., and Rodell T.C. Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: preliminary safety and immunogenicity results from a phase 1 trial. Proc Am Soc Clin Oncol (2005) 2571
44. Regulez P., Arilla M.C., Bikandi J., Quindos G., Cisterna R., and Ponton J. Identification of antigens reacting with anti-Candida albicans germ tube antibodies. Eur J Epidemiol 8 3 (1992) 356-361